600252:SSEGuangxi Wuzhou Zhongheng Group Co., Ltd. Class A Analysis

The stock is trading at CNY 2.23, which is well above the DCF‑derived fair value of CNY 1.29, indicating a pricing premium. Technical indicators are bearish: the 20‑day SMA (2.31) lies below both the 50‑day (2.44) and 200‑day (2.68) averages, the MACD histogram is negative and the signal is labeled bearish, while the RSI sits at 36, suggesting limited upside momentum. Volume is decreasing, and the price is hovering just above the identified support of CNY 2.17 but below the resistance of CNY 2.51, leaving little room for a rally. Fundamentally, the company reports a –52 % revenue decline, negative operating and profit margins (‑4 % and ‑26 % respectively), and a trailing EPS of –0.13, underscoring earnings weakness. Despite a strong cash position of CNY 3.79 bn, debt remains high at CNY 2.11 bn, yielding a debt‑to‑equity ratio of 31.8 % and a negative ROE of ‑7.7 %. The sector – specialty and generic pharmaceuticals in China – carries medium regulatory risk and the stock’s beta of 0.36 points to lower systematic volatility, yet the 30‑day volatility of 26 % and a max drawdown of ‑27 % signal considerable price swings. Overall, the combination of over‑priced market valuation, deteriorating fundamentals, and bearish technical signals suggests caution.